Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30499578 | 1.00 | HTT (0.56) | HTTLMNATHRBKDM4EMEN1 | |
| SCHEMBL29904657 | 1.00 | HTT (0.56) | HTTLMNATHRBKDM4EMEN1 | |
| SCHEMBL553501 | 0.83 | ALDH1A1 (0.59) | HTTLMNAKDM4EMEN1MAPT | |
| SCHEMBL9618923 | 0.81 | IDO1 (0.50) | HTTLMNATHRBKDM4EMEN1 | |
| SCHEMBL27497018 | 0.80 | ALDH1A1 (0.43) | HTTLMNATHRBKDM4EMEN1 | |
| SCHEMBL15961769 | 0.79 | HSD17B10 (0.50) | HTTLMNAMEN1MAPTKMT2A | |
| SCHEMBL1803989 | 0.78 | HSD17B10 (0.61) | HTTTHRBKDM4EMEN1MAPT | |
| SCHEMBL11153750 | 0.77 | HTT (0.52) | HTTLMNAKDM4EMEN1MAPT | |
| SCHEMBL21771152 | 0.77 | ALDH1A1 (0.49) | HTTLMNAKDM4EMEN1MAPT | |
| SCHEMBL6537307 | 0.77 | EP300 (0.46) | HTTLMNAKDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12163968-B2 | Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers | BIO-RAD LABORATORIES, INC. (US) | 2024-12-10 | — | — | US | claimed |
| CN-115252588-B | Application of 1, 4-hydroquinone and/or 1, 4-hydroquinone derivative in preparing anti-novel coronavirus medicine | 山东达因海洋生物制药股份有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-115252588-A | Application of 1, 4-hydroquinone and/or 1, 4-hydroquinone derivative in preparation of anti-novel coronavirus medicines | 山东达因海洋生物制药股份有限公司 | 2022-11-01 | — | — | CN | claimed |
| US-12163968-B2 | Preparation of nucleated RBC (NRBC) analogs for use as reference hematology controls in automated hematology analyzers | BIO-RAD LABORATORIES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-115252588-B | Application of 1, 4-hydroquinone and/or 1, 4-hydroquinone derivative in preparing anti-novel coronavirus medicine | 山东达因海洋生物制药股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4208021-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | Bio-Rad Laboratories, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| CN-116097093-A | Preparation of Nucleated RBC (NRBC) analogs for use as reference blood controls in automated blood analyzers | 生物辐射实验室股份有限公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-115252588-A | Application of 1, 4-hydroquinone and/or 1, 4-hydroquinone derivative in preparation of anti-novel coronavirus medicines | 山东达因海洋生物制药股份有限公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022051443-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | BIO-RAD LABORATORIES, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| US-20220065878-A1 | PREPARATION OF NUCLEATED RBC (NRBC) ANALOGS FOR USE AS REFERENCE HEMATOLOGY CONTROLS IN AUTOMATED HEMATOLOGY ANALYZERS | BIO-RAD LABORATORIES, INC. | 2022-03-03 | — | — | US | disclosed |
| US-20170336728-A1 | ULTRAVIOLET CURABLE LIQUID COMPOSITION, ULTRAVIOLET CURING INKJET INK, ULTRAVIOLET CURING WET ELECTROPHOTOGRAPHIC LIQUID DEVELOPER, ULTRAVIOLET CURING ELECTROSTATIC INKJET INK, AND IMAGE FORMING METHOD USING THEREOF | CANON KABUSHIKI KAISHA (JP) | 2017-11-23 | — | — | US | disclosed |
| US-8114580-B2 | Simulation of normal fresh blood platelets for reference control | BIO-RAD LABORATORIES, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| EP-2376908-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | Bio-Rad Laboratories, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010083130-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | BIO-RAD LABORATORIES, INC. (US) | 2010-07-22 | — | — | WO | disclosed |
| US-20100178647-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | BIO-RAD LABORATORIES, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| EP-0994871-B1 | NOVEL SUBSTITUTED NAPHTHOPYRANS | TRANSITIONS OPTICAL INC (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-0994871-A4 | NOVEL SUBSTITUTED NAPHTHOPYRANS | TRANSITIONS OPTICAL INC (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-0994871-A1 | NOVEL SUBSTITUTED NAPHTHOPYRANS | TRANSITIONS OPTICAL, INC. (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1998055477-A1 | NOVEL SUBSTITUTED NAPHTHOPYRANS | TRANSITIONS OPTICAL, INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| US-5658501-A | Substituted naphthopyrans | TRANSITIONS OPTICAL, INC. (US) | 1997-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178647-A1 | SIMULATION OF NORMAL FRESH BLOOD PLATELETS | MPL, THPO, PFKP | HTT 1081/4885LMNA 2174/4885THRB 2843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.